Objectives. To study the efficacy of the drug Cytoflavin in patients with diabetic polyneuropathy (DPN) by assessing the blood tumor necrosis factor-α (TNF-α) concentration. Materials and methods. An open, comparative, prospective observation of patients with a history of DPN for more than five years and high blood TNF-α levels was carried out. All patients received basic oral combined hypoglycemic therapy; patients in group 1 received Cytoflavin (10 ml per 200 ml 0.9% sodium chloride i.v.) for 10 days, followed by switching to oral Cytoflavin, 2 tablets twice a day for one month. The main indication for the use of Cytoflavin was the presence of cerebrovascular disease in all the patients studied. The severity of the clinical manifestations of DPN and patients’ quality of life (QoL) were assessed, and TNF-α levels were determined as an indicator of inflammation. Results. Cytoflavin use was associated with increases in quality of life indicators, decreases in the severity of sensory disturbances, and decreases in TNF-α levels, which may indicate a possible anti-inflammatory mechanism of action for this drug. Conclusions. Use of Cytoflavin can inhibit inflammation and reduce the severity of sensory disorders in patients with DPN.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Maffi, P. and Secchi, A., “The burden of diabetes: Emerging data,” Dev. Ophthalmol., 60, No. 6, 1–5 (2017).
Liu, X., Xu, Y., An, M., and Zeng, Q., “The risk factors for diabetic peripheral neuropathy: a meta-analysis,” PLoS One, 14, No. 2, e0212574 (2019).
Dedov, I. I., Shestakova, M. V., and Vikulova, O. K., “State Diabetes Mellitus Register of the Russian Federation: Status in 2014 and prospects for development,” Sakhar. Diabet, 18, No. 3, 5–23 (2015).
Callaghan, B. C., Cheng, H. T., et al., “Diabetic neuropathy: clinical manifestations and current treatments,” Lancet Neurol., 11, No. 6, 521–534 (2012).
Zubair, M. and Ahmad, J., “Role of growth factors and cytokines in diabetic foot ulcer healing: A detailed review,” Rev. Endocr. Metab. Disord., 20, No. 2, 207–217 (2019).
Kartika, R. W., Alwi, I., Suyatna, F. D., et al., “The role of VEGF, PDGF, and IL-6 on diabetic foot ulcer after platelet rich fibrin + hyaluronic therapy,” Heliyon, 7, No. 9, e07934 (2021).
Várkonyi, T., Körei, A., Putz, Z., et al., “Advances in the management of diabetic neuropathy,” Minerva Med., 108, No. 5, 419–437 (2017).
Thakur, V., Sadanandan, J., and Chattopadhyay, M., “High-mobility group box 1 protein signaling in painful diabetic neuropathy,” Int. J. Mol. Sci., 21, No. 3, 881 (2020).
Davydov, O. S., Yakhno, N. N., Kukushkin, M. L., et al., Neuropathic Pain. Clinical Guidelines for Diagnosis and Treatment, Russian Association for the Study of Pain, Moscow (2018), pp. 1–88.
Khramilin, V. N. and Demidova, I. Yu., “Features of the diagnosis and treatment of diabetic polyneuropathy in elderly patients,” Effektiv. Farmakoter., 16, No. 12, 42–54 (2020).
Attal, N., “Pharmacological treatments of neuropathic pain: The latest recommendations,” Rev. Neurol (Paris), 175, No. 1–2, 46–50 (2019).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 123, No. 4, pp. 68–71, April, 2023.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Shchepankevich, L.A., Pervuninskaya, M.A., Gribacheva, I.A. et al. The Role of Inflammation in the Development of Diabetic Polyneuropathy and the Potential for Its Correction. Neurosci Behav Physi 53, 1373–1376 (2023). https://doi.org/10.1007/s11055-023-01528-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-023-01528-z